NCT04850755View on ClinicalTrials.gov

A Phase I Dose Escalation Study of Selinexor Plus Nivolumab and Ipilimumab in Advanced/Metastatic Solid Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

March 8, 2021

Primary Completion Date

March 17, 2025

Study Completion Date

March 17, 2025

Conditions
Advance Solid MalignanciesMetastatic Solid Malignancies
Interventions
DRUG

Selinexor in combination with nivolumab and ipilimumab

Patients will commence at dose level 1. One cycle is 42 days (6 weeks) for all three agents. At dose level 1, selinexor will be dosedorally weekly, and nivolumab at 2 weekly + ipilimumab 1mg/kg 6 weekly. Patients can have dosing interruptions or reductions of any drug independently of one another, depending on the drug causing the toxicity

Trial Locations (1)

Unknown

National University Hospital, Singapore, Singapore

All Listed Sponsors
lead

National University Hospital, Singapore

OTHER

NCT04850755 - A Phase I Dose Escalation Study of Selinexor Plus Nivolumab and Ipilimumab in Advanced/Metastatic Solid Malignancies | Biotech Hunter | Biotech Hunter